TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06250049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetic foot care protocol
Description: Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group education sessions for patients and/or caregivers
Description: Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
Study: NCT05778136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
Study: NCT05154032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Float-REST Therapy
Description: Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
Study: NCT05389683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elimination Diet
Description: An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
Study: NCT05534737

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: usual care of social services
Study: NCT04790747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
Study: NCT05807399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 1,000mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
Study: NCT05897385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine
Description: Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
Study: NCT06135246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy
Description: Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
Study: NCT06384820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered Intravenous (IV) infusion every three weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered Intravenous (IV) infusion every three weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: IV infusion Q3W
Study: NCT05897385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intraperitoneal 20ml of 0.9% normal saline
Study: NCT04990596

Intervention type: BIOLOGICAL
Intervention: additional blood sample
Description: One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
Study: NCT05807399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2:.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2:.
Study: NCT04990596

Intervention type: BIOLOGICAL
Intervention: additional blood sample
Description: One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.

Intervention type: BIOLOGICAL
Intervention: additional blood sample
Description: One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.

Intervention type: BIOLOGICAL
Intervention: additional blood sample
Description: One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.

Intervention type: BIOLOGICAL
Intervention: additional blood sample
Description: One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
Study: NCT04989712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Participants randomised to one of the three exposures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Participants randomised to one of the three exposures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Participants randomised to one of the three exposures
Study: NCT05866978

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)
Description: The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
Study: NCT05504590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tuohy needle group
Description: Ultrasound-guided caudal epidural block with Touhy needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quincke needle group
Description: Ultrasound-guided caudal epidural block with Quincke needle
Study: NCT06145568

Intervention type: OTHER
Intervention: Pregnant Women
Description: We want to quantify Minority Americans at risk of pregnancy complications
Study: NCT05541341

Intervention type: OTHER
Intervention: tisagenlecleucel
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Intervention type: OTHER
Intervention: tisagenlecleucel
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Intervention type: OTHER
Intervention: tisagenlecleucel
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
Study: NCT06499103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
Study: NCT04316559

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV734
Description: biased agonist at mu opioid receptors
Study: NCT05237362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Saga Stories
Description: Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
Study: NCT06065332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velez Intense Hydration Mask® (biotech cellulose face mask)
Description: Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velez Intense Hydration Mask® (biotech cellulose face mask)
Description: Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
Study: NCT04867083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV bitherapie
Description: 1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARV bitherapie
Description: 1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day
Study: NCT05512962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Single suprachoroidal Administration of Triamcinolone acetonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Single suprachoroidal Administration of Triamcinolone acetonide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated Suprachoroidal Microcatheter
Description: Ophthalmic Adminstration Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated Suprachoroidal Microcatheter
Description: Ophthalmic Adminstration Device
Study: NCT06127147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT
Description: The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-IMT
Description: The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
Study: NCT05029310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Oral Product
Description: interaction study
Study: NCT06289946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NitroBid
Description: We will apply nirobid to the wrist prior to left heart catheterization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We will apply placebo moisturizing cream to the wrist
Study: NCT05930847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Game Application
Description: The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
Study: NCT05660213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab + Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Apatinib
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab+Apatinib
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study: NCT05930847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of medication for asthma
Description: The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of medication for asthma
Description: The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
Study: NCT05384834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #HerHeart tool
Description: An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
Study: NCT06319781

Intervention type: OTHER
Intervention: Observational
Description: The study is a prospective non-interventional, observational study.

Intervention type: OTHER
Intervention: Observational
Description: The study is a prospective non-interventional, observational study.

Intervention type: OTHER
Intervention: Observational
Description: The study is a prospective non-interventional, observational study.

Intervention type: OTHER
Intervention: Observational
Description: The study is a prospective non-interventional, observational study.
Study: NCT04800744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender peppermint elequil aromatab
Description: Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweet almond oil elequil aromatab
Description: Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
Study: NCT05660213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab+Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study: NCT05274828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H7-Coil Deep TMS for CUD
Description: The Study group will receive dTMS treatment three times a day for ten days.
Study: NCT05075707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy.
Description: Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Description: Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
Study: NCT03924310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetBack System Active
Description: Commercially available hand prosthesis with feedback device turned on

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetBack System Passive
Description: Commercially available hand prosthesis with feedback device turned off
Study: NCT05806736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (real stimulation)
Description: Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation (sham stimulation)
Description: Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.